PMID- 38364692
OWN - NLM
STAT- Publisher
LR  - 20240216
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 185
DP  - 2024 Feb 15
TI  - Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade 
      endometrial endometrioid carcinoma: Clinicopathologic characteristics and future 
      directions.
PG  - 25-32
LID - S0090-8258(24)00074-X [pii]
LID - 10.1016/j.ygyno.2024.01.048 [doi]
AB  - OBJECTIVES: To study the expression of HER2 in high-grade FIGO3 endometrial 
      endometroid carcinoma (EEC) and to correlate our findings with the 
      clinicopathologic characteristics of this tumor. METHODS: HER2 expression by 
      immunohistochemistry (IHC) was performed on 10% formalin-fixed paraffin embedded 
      tissue on cases diagnosed as FIGO3 EEC. HER2 expression was interpreted as 
      negative (0), low (1+ and 2+) or positive (3+) using similar criteria as in the 
      breast. HER2 amplification by Fluorescence in situ hybridization (FISH) was 
      performed on cases interpreted as 2+ and 3+ by IHC. RESULTS: One hundred and 
      forty-three FIGO3 EEC were identified. Of these, 70 (49%) cases were HER2 
      negative (IHC 0), and 73 (51%) cases expressed/amplified HER2 by IHC and/or FISH. 
      Of the 73 cases expressing or amplifying HER2, 59 cases were IHC 1+, 12 cases 
      were IHC 2+, and 2 cases were IHC 3+. FISH testing was performed in 12 cases. 
      Only one of the two HER2 IHC 3+ cases showed HER2 gene amplification by FISH and 
      the other 11 cases were not amplified. The 5-year overall survival (OS) rate for 
      HER2 IHC 1+ cases was 92.20% (95% CI: 83.97-100.00), and the 5-year OS rate for 
      HER2 IHC 2+/3+ cases was 89.50% (95% CI: 56.41-100.00). CONCLUSION: Our findings 
      indicate that about one half of FIGO3 EEC variably expresses HER2 and with the 
      emerging concept of "HER2 low", anti-HER2 agents may be explored as potential 
      therapeutic options in these patients, for possible survival benefits.
CI  - Copyright (c) 2024 Elsevier Inc. All rights reserved.
FAU - Abada, Evi
AU  - Abada E
AD  - Department of Pathology and Laboratory Medicine, Women and Infants Hospital, & 
      The Warren Alpert Medical School of Brown University, 101 Dudley Street, 
      Providence, RI 02905, USA. Electronic address: gs5839@wayne.edu.
FAU - Kim, Seongho
AU  - Kim S
AD  - Biostatistics and Bioinformatics Core, Karmanos Cancer Institute, Department of 
      Oncology, Wayne State University School of Medicine, 4100 John R. Road, Detroit, 
      MI 48201, USA.
FAU - Jang, Hyejeong
AU  - Jang H
AD  - Biostatistics and Bioinformatics Core, Karmanos Cancer Institute, Department of 
      Oncology, Wayne State University School of Medicine, 4100 John R. Road, Detroit, 
      MI 48201, USA.
FAU - Kheil, Mira
AU  - Kheil M
AD  - Department of Pathology, Wayne State University School of Medicine/Detroit 
      Medical Center, 3990 John R Road, Detroit, MI 48201, USA.
FAU - Singh, Kamaljeet
AU  - Singh K
AD  - Department of Pathology and Laboratory Medicine, Women and Infants Hospital, & 
      The Warren Alpert Medical School of Brown University, 101 Dudley Street, 
      Providence, RI 02905, USA.
FAU - Bandyopadhyay, Sudeshna
AU  - Bandyopadhyay S
AD  - Department of Pathology, Wayne State University School of Medicine/Detroit 
      Medical Center, 3990 John R Road, Detroit, MI 48201, USA.
FAU - Ali-Fehmi, Rouba
AU  - Ali-Fehmi R
AD  - Department of Pathology, Wayne State University School of Medicine/Detroit 
      Medical Center, 3990 John R Road, Detroit, MI 48201, USA.
FAU - Quddus, M Ruhul
AU  - Quddus MR
AD  - Department of Pathology and Laboratory Medicine, Women and Infants Hospital, & 
      The Warren Alpert Medical School of Brown University, 101 Dudley Street, 
      Providence, RI 02905, USA.
LA  - eng
PT  - Journal Article
DEP - 20240215
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
SB  - IM
OTO - NOTNLM
OT  - Anti-HER2 therapy in FIGO3 endometrial Endometrioid carcinoma
OT  - FIGO 3 endometrial Endometrioid carcinoma
OT  - HER2 expression in FIGO3 endometrial Endometrioid carcinoma
OT  - HER2 low in FIGO3 endometrial Endometrioid carcinoma
COIS- Declaration of competing interest All authors declare that they have no conflicts 
      of interest related to this manuscript.
EDAT- 2024/02/17 10:42
MHDA- 2024/02/17 10:42
CRDT- 2024/02/16 18:14
PHST- 2023/10/24 00:00 [received]
PHST- 2024/01/12 00:00 [revised]
PHST- 2024/01/29 00:00 [accepted]
PHST- 2024/02/17 10:42 [medline]
PHST- 2024/02/17 10:42 [pubmed]
PHST- 2024/02/16 18:14 [entrez]
AID - S0090-8258(24)00074-X [pii]
AID - 10.1016/j.ygyno.2024.01.048 [doi]
PST - aheadofprint
SO  - Gynecol Oncol. 2024 Feb 15;185:25-32. doi: 10.1016/j.ygyno.2024.01.048.